PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 8, 2026JAMA Neurology2 citations

Interstitial Lung Disease as a Late Occurrence in Ocrelizumab-Treated Patients With Multiple Sclerosis

View Full Paper
AŻAnna ŻurawskaACAnne H. CrossKRKatarzyna Rzeszutek

Key Points

  • This research aims to explore the occurrence of interstitial lung disease in multiple sclerosis patients treated with ocrelizumab.
  • Case series involving 6 patients with multiple sclerosis
  • Long-term treatment with ocrelizumab
  • Observation of respiratory symptoms
  • Interstitial lung disease was identified in 6 patients
  • All patients were on long-term ocrelizumab therapy
  • Symptoms involved respiratory distress and imaging findings

Abstract

This case series describes 6 cases of interstitial lung disease among patients with multiple sclerosis receiving long-term treatment with ocrelizumab.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Żurawska et al. (2026) studied this question.

synapsesocial.com/papers/69d5f0ee74eaea4b11a7a60ehttps://doi.org/10.1001/jamaneurol.2026.0548
Ask AI
Helpful
Bookmark
Share
View Full Paper